Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Blood (2024) 144 (Supplement 1): 226.

https://doi.org/10.1182/blood-2024-205457

Published: 2024

Journal Articles

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Blood (2022) 140 (Supplement 1): 6279–6281.

https://doi.org/10.1182/blood-2022-169696

Published: 2022

Journal Articles

Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS

Blood (2017) 130 (Supplement 1): 1705.

https://doi.org/10.1182/blood.V130.Suppl_1.1705.1705

Published: 2017

Journal Articles

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Eve Poret, Fanny Angelot Delettre, Sabeha Biichle, Anne Roogy, Louis Benazet, Maider Pagadoy, Chrystelle Vidal, Franck Leroux, Véronique Harrivel, Christophe Ferrand, PhD, Veronique Salaun, Zehaira Benseddik, Julien Guy, Marie Christine Jacob, Christophe Roumier, Jean Feuillard, Liliana Vila, Lucile Baseggio, Adriana Plesa, Christine Arnoulet, B Benet, Bernard Drenou, MD, Veronique Latger Cannard, Marie-Christine Bene, MD, Michel Ticchioni, Daniel Lusina, Valerie Bardet, Magalie LE Garff Tavernier, Elizabeth Macintyre, MD PhD, Vahid Asnafi, MDPhD, Maria Elena Noguera, Sabrina Bouyer, Carine Lecoq Lafon, Mikael Roussel, MD PhD, Fabrice Jardin, Francoise Solly, MD, Lydia Campos, MD PhD, Anne Galoisy, Anne Arnaud, Sylvie Daliphard, Franck Genevieve, MD PhD, Romaric Lacroix, Françoise Schillinger, Estelle Seilles, Delphine Binda, Eric Deconinck, Philippe Saas, PhD, Francine Garnache Ottou, PhD

Blood (2015) 126 (23): 3812.

https://doi.org/10.1182/blood.V126.23.3812.3812

Published: 2015

Journal Articles

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Blood (2015) 125 (23): 3618–3626.

https://doi.org/10.1182/blood-2015-01-620781

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

Blood (2013) 122 (20): 3521–3532.

https://doi.org/10.1182/blood-2013-03-493163

Published: 2013

Includes: Supplemental data

Journal Articles

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

Nicolas Chapuis, Sophie Park, Laurent Leotoing, Jerome Tamburini, Frederique Verdier, Valerie Bardet, Alexa S. Green, Lise Willems, Fabrice Agou, Norbert Ifrah, François Dreyfus, Georges Bismuth, Veronique Baud, Catherine Lacombe, Patrick Mayeux, Didier Bouscary

Blood (2010) 116 (20): 4240–4250.

https://doi.org/10.1182/blood-2009-12-260711

Published: 2010

Includes: Supplemental data

Journal Articles

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

Alexa S. Green, Nicolas Chapuis, Thiago Trovati Maciel, Lise Willems, Mireille Lambert, Christophe Arnoult, Olivier Boyer, Valerie Bardet, Sophie Park, Marc Foretz, Benoit Viollet, Norbert Ifrah, François Dreyfus, Olivier Hermine, Ivan Cruz Moura, Catherine Lacombe, Patrick Mayeux, Didier Bouscary, Jerome Tamburini

Blood (2010) 116 (20): 4262–4273.

https://doi.org/10.1182/blood-2010-02-269837

Published: 2010

Includes: Supplemental data

Journal Articles

Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-β signaling at the bipotent erythro-megakaryocytic progenitor stage

Voahangy Randrianarison-Huetz, Benoit Laurent, Valérie Bardet, Gerard C. Blobe, François Huetz, Dominique Duménil

Blood (2010) 115 (14): 2784–2795.

https://doi.org/10.1182/blood-2009-09-241752

Published: 2010

Includes: Supplemental data

Journal Articles

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

Jerome Tamburini, Alexa S. Green, Valerie Bardet, Nicolas Chapuis, Sophie Park, Lise Willems, Madalina Uzunov, Norbert Ifrah, François Dreyfus, Catherine Lacombe, Patrick Mayeux, Didier Bouscary

Blood (2009) 114 (8): 1618–1627.

https://doi.org/10.1182/blood-2008-10-184515

Published: 2009

Includes: Supplemental data

Journal Articles

A critical role for Lyn in acute myeloid leukemia

Cédric Dos Santos, Cécile Demur, Valérie Bardet, Nais Prade-Houdellier, Bernard Payrastre, Christian Récher

Blood (2008) 111 (4): 2269–2279.

https://doi.org/10.1182/blood-2007-04-082099

Published: 2008

Includes: Supplemental data

Journal Articles

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Blood (2008) 111 (2): 574–582.

https://doi.org/10.1182/blood-2007-06-096370

Published: 2008

Includes: Supplemental data

Journal Articles

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways

Jerome Tamburini, Nicolas Chapuis, Valérie Bardet, Sophie Park, Pierre Sujobert, Lise Willems, Norbert Ifrah, François Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary

Blood (2008) 111 (1): 379–382.

https://doi.org/10.1182/blood-2007-03-080796

Published: 2008

Includes: Supplemental data

Journal Articles

PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.

Sophie Park, MD, Nicolas Chapuis, MD, Valerie Bardet, PhD, Lise Willems, MD, Jerome Tamburini, MD, Zachary A. Knight, PhD, Kevan M. Shokat, PhD, Nabih Azar, MD, Norbert Ifrah, MD, PhD, Francois Dreyfus, MD, PhD, Patrick Mayeux, MD, Catherine Lacombe, MD, PhD, Didier Bouscary, MD, PhD

Blood (2007) 110 (11): 876.

https://doi.org/10.1182/blood.V110.11.876.876

Published: 2007

Journal Articles

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients

Jerome Tamburini, Caroline Elie, Valérie Bardet, Nicolas Chapuis, Sophie Park, Philippe Broët, Pascale Cornillet-Lefebvre, Bruno Lioure, Valérie Ugo, Odile Blanchet, Norbert Ifrah, Francis Witz, François Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary

Blood (2007) 110 (3): 1025–1028.

https://doi.org/10.1182/blood-2006-12-061283

Published: 2007

Journal Articles

Constitutive Phosphoinositide-3kinase Activation Represents a Good Prognostic Factor in De Novo AML Patients under 60 Years.

Jerome Tamburini, Caroline Elie, Valerie Bardet, Sophie Park, Philippe Broet, Pascale Cornillet Lefebvre, Bruno Lioure, Norbert Ifrah, Francis Witz, Jean Luc Harousseau, Francois Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary

Blood (2006) 108 (11): 1895.

https://doi.org/10.1182/blood.V108.11.1895.1895

Published: 2006

Journal Articles

Lyn Kinase Is Constitutively Activated, Controls the mTOR/p70S6K/4E-BP1 Pathway and Regulates Cell Proliferation in Acute Myeloid Leukemia.

Christian Recher, MD, Cedric Dos Santos, MD, Cecile Demur, MD, Valerie Bardet, MD,PhD, Nais Prade-Houdellier, Guy Laurent, MD,PhD, Bernard Payrastre, PhD

Blood (2006) 108 (11): 1946.

https://doi.org/10.1182/blood.V108.11.1946.1946

Published: 2006

Journal Articles

Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia.

Jerome Tamburini, Nicolas Chapuis, Valerie Bardet, Sophie Park, Frederique Verdier, Francois Dreyfus, Catherine Lacombe, Didier Bouscary

Blood (2006) 108 (11): 1904.

https://doi.org/10.1182/blood.V108.11.1904.1904

Published: 2006

Journal Articles

Assessment of MYH9- Related Syndromes among a Series of Patients with Constitutional Macrothrombocytopenia (MT).

Nicole Schlegel, Beatrice Saposnik, Sylvie Binard, Sandrine Elbaz, Odile Fenneteau, Valerie Bardet, Benedicte Gerard, Paquita Nurden, French Ref Center for Inherited Plat Disorders

Blood (2006) 108 (11): 700.

https://doi.org/10.1182/blood.V108.11.700.700

Published: 2006

Journal Articles

Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

Blood (2005) 106 (3): 1063–1066.

https://doi.org/10.1182/blood-2004-08-3225

Published: 2005

NARROW

Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-β signaling at the bipotent erythro-megakaryocytic progenitor stage

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

A critical role for Lyn in acute myeloid leukemia

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways

PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients

Constitutive Phosphoinositide-3kinase Activation Represents a Good Prognostic Factor in De Novo AML Patients under 60 Years.

Lyn Kinase Is Constitutively Activated, Controls the mTOR/p70S6K/4E-BP1 Pathway and Regulates Cell Proliferation in Acute Myeloid Leukemia.

Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia.

Assessment of MYH9- Related Syndromes among a Series of Patients with Constitutional Macrothrombocytopenia (MT).

Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only